IMU Biosciences

IMU Biosciences is a UK immune-profiling company that raised an oversubscribed £40m ($53m) Series A on 2 June 2026, co-led by IQ Capital and Molten Ventures with the British Business Bank co-investing. The company's core technology extracts more than 100 million immune-system data points from a single blood sample, generating a high-dimensional profile of an individual's immune state that would previously have required multiple specialist assays and far larger volumes of blood.

Immune profiling sits at the intersection of diagnostics, drug development and precision medicine. High-resolution immune data is valuable for identifying biomarkers of disease, stratifying patients in clinical trials, monitoring immunotherapy response and understanding why individuals differ in their susceptibility to infection or autoimmune conditions. IMU's approach, compressing this data acquisition into a single-tube blood draw, reduces the cost and logistical complexity of immune phenotyping enough to make it viable for large-cohort studies and eventually routine clinical use.

The oversubscribed Nature of the round at Series A reflects strong institutional confidence in the underlying Science at a stage when most life-Science companies still face significant proof-of-concept risk. The British Business Bank's co-investment continues a pattern of public-sector participation in UK deep-tech life sciences rounds (it also co-invested in OQC's quantum Series C in the same week). IMU Biosciences sits in a segment where UK academic excellence in immunology, particularly from institutions such as the Wellcome Sanger Institute and the Francis Crick Institute, provides a competitive research pipeline advantage.